TheraCryf (LSE:TCF) EBITDA Margin %: 0.00% (As of Sep. 2025)


What is TheraCryf EBITDA Margin %?

TheraCryf LSE:TCF EBITDA Margin % is 0.00% as of Sep. 2025. The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, TheraCryf ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. TheraCryf's EBITDA for the six months ended in Sep. 2025 was £-1.37 Mil. TheraCryf's Revenue for the six months ended in Sep. 2025 was £0.00 Mil. Therefore, TheraCryf's EBITDA margin for the quarter that ended in Sep. 2025 was 0.00%.

TheraCryf  (LSE:TCF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

TheraCryf EBITDA Margin % Related Terms

TheraCryf EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for TheraCryf's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TheraCryf EBITDA Margin % Chart

TheraCryf Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,642.27 0.00 -1,144.12 -895.96 0.00

TheraCryf Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -366.92 0.00 0.00 0.00 0.00

LSE:TCF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, TheraCryf's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TheraCryf EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TheraCryf's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where TheraCryf's EBITDA Margin % falls into.


TheraCryf EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

TheraCryf's EBITDA Margin % for the fiscal year that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2025 )/Revenue (A: Mar. 2025 )
=-2.046/0
= %

TheraCryf's EBITDA Margin % for the quarter that ended in Sep. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-1.367/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
TheraCryf (LSE:TCF) has a EBITDA Margin % of 0.00% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TheraCryf and its competitors. According to the industry distribution chart, TheraCryf ranks #999999 out of 945 companies in the Biotechnology industry.
Is TheraCryf's EBITDA Margin % too high?
TheraCryf's current EBITDA Margin % is 0.00%. Based on the distribution chart, TheraCryf ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does TheraCryf's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TheraCryf ranks #999999 out of 945 companies for EBITDA Margin %. This places TheraCryf in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TheraCryf and its competitors. TheraCryf's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TheraCryf stock overvalued right now?
TheraCryf (LSE:TCF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TheraCryf (LSE:TCF), the current EBITDA Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TheraCryf Business Description

Address Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.